SPOTLIGHT: Investors cheer Progen data


Australia's Progen Industries saw its share surge after researchers announced that its experimental liver cancer drug demonstrated statistically significant results. Patients taking PI-88 following the removal of a cancerous tumor went an average of 30 weeks before it grew back, compared to 17 weeks for patients who weren't taking the drug. Release | Report

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.